



**HELMHOLTZ
ZENTRUM FÜR
INFEKTIONSFORSCHUNG**

**This is a pre- or post-print of an article published in
Maurer, C.K., Steinbach, A., Hartmann, R.W.
Development and validation of a UHPLC-MS/MS procedure for
quantification of the Pseudomonas Quinolone Signal in
bacterial culture after acetylation for characterization
of new quorum sensing inhibitors
(2013) Journal of Pharmaceutical and Biomedical Analysis,
86, pp. 127-134.**

1

1Development and validation of a UHPLC-MS/MS procedure for
2quantification of the Pseudomonas Quinolone Signal in bacterial
3culture after acetylation for characterization of new quorum
4sensing inhibitors

5

6Christine K. Maurer^a, Anke Steinbach^{a*}, Rolf W. Hartmann^{a,b*}

7

8^a *Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Campus C2.3, D-
966123 Saarbrücken, Germany; christine.maurer@helmholtz-hzi.de,*

10*anke.steinbach@helmholtz-hzi.de, rolf.hartmann@helmholtz-hzi.de*

11^b *Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, D-
1266123 Saarbrücken, Germany*

13

14

15Corresponding authors at: Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS),
16Campus C2.3, D-66123 Saarbrücken, Germany.

17Tel.: +49 681 302 70343 (Anke Steinbach); +49 681 302 70300 (Rolf W. Hartmann); fax: +49
18681 302 70308

19E-mail addresses: anke.steinbach@helmholtz-hzi.de; rolf.hartmann@helmholtz-hzi.de

20

1ABSTRACT

2The appearance of antibiotic resistance requires novel therapeutic strategies. One
3approach is to selectively attenuate bacterial pathogenicity by interfering with bacterial
4cell-to-cell communication known as quorum sensing. The *pqs* quorum sensing system
5of *Pseudomonas aeruginosa* employs as signal molecule the Pseudomonas Quinolone
6Signal (PQS; 2-heptyl-3-hydroxy-4-(1*H*)-quinolone), a key contributor to virulence and
7biofilm formation. Thus, interference with PQS production is considered as promising
8approach for the development of novel anti-infectives. Therefore, in this study, we
9developed and validated an ultra-high performance liquid chromatographic-tandem
10mass spectrometric approach for reliable quantification of PQS in *P. aeruginosa*
11cultures for activity determination of new quorum sensing inhibitors. The poor
12chromatographic properties of PQS reported by others could be overcome by fast
13microwave-assisted acetylation. The validation procedure including matrix effects,
14recovery, process efficiency, selectivity, carry-over, accuracy and precision, stability of
15the processed sample, and limit of quantification demonstrated that the method fulfilled
16all requirements of common validation guidelines. Its applicability was successfully
17proven in routine testing. In addition, two-point calibration was shown to be applicable
18for fast and reliable PQS quantification saving time and resources. In summary, the
19described method provides a powerful tool for the discovery of new quorum sensing
20inhibitors as potential anti-infectives and illustrated the usefulness of chemical
21derivatization, acetylation, in liquid chromatography-mass spectrometry analysis.

22

23**Keywords:** UHPLC-MS/MS; acetylation; *Pseudomonas* Quinolone Signal; quorum
24sensing inhibitors; validation; two-point calibration

11. Introduction

2 The emergence and spread of antimicrobial resistance in life-threatening pathogens
3 such as *P. aeruginosa* are mainly attributed to the overuse of bactericidal antibiotics
4 selecting for resistant mutants [1]. Moreover, bacteria living in biofilms exhibit higher
5 resistance against antibiotics than planktonic cultures [2]. Thus, innovative therapeutic
6 approaches such as anti-virulence and anti-biofilm strategies with the aim of reducing
7 pathogenicity without affecting bacterial viability are in the focus of interest [3]. In this
8 context, interference with bacterial quorum sensing (QS) has received special attention
9 as potential therapeutic strategy for the development of novel anti-infective drugs [4,5].
10 QS functions *via* a cell-density dependent cell-to-cell communication system employing
11 signal molecules that interact with response regulators thereby controlling the
12 expression of genes *e.g.* involved in pathogenicity [6]. This allows the individual
13 bacterial cells to coordinate group behaviors such as the production of virulence factors
14 and biofilm formation.

15 The opportunistic human pathogen *P. aeruginosa* uses as signal molecules *N*-acyl-L-
16 homoserine lactones (AHLs) for the *las*, *rhl* and 2-alkyl-4-(1*H*)-quinolones (AQs) for
17 the *pqs* QS system [7]. The key player in the latter system is the Pseudomonas
18 Quinolone Signal (PQS; 2-heptyl-3-hydroxy-4-(1*H*)-quinolone) [7], which is unique for
19 *P. aeruginosa*. It acts as a strong agonist of the transcriptional regulator PqsR driving
20 the expression of various virulence factors [8]. Furthermore, PQS down-regulates innate
21 immune responses [9]. Regarding biofilms, PQS is supposed to function in the release
22 of extracellular DNA, a main biofilm matrix component [10], thus promoting biofilm
23 formation. The latter should be reduced by inhibiting PqsD, a key enzyme in PQS
24 biosynthesis [11,12]. In fact, we could show recently that (2-nitrophenyl)
25 (phenyl)methanol (2NPPM), a rationally designed inhibitor of PqsD, was able to reduce

1PQS production and biofilm formation [13]. In addition, reduction of AQ production
2was accompanied by reduced bacterial dissemination and mortality in infected mice
3[14]. In summary, interception of QS by PQS interference is considered as a promising,
4novel approach for the development of anti-virulence and anti-biofilm compounds
5[15,16].

6 Therefore, a reliable analytical method is needed for the determination of PQS
7concentrations in bacterial cultures for discovery and biological evaluation of QS
8inhibitors (QSIs). To date, several approaches for quantification of PQS have been
9described, among them, methods not suitable for inhibitor testing such as unselective
10thin layer chromatography [17], capillary electrophoresis with cyclic voltammetry and
11amperometry [18], and time-consuming gas chromatography-mass spectrometry (GC-
12MS) [19]. Liquid chromatography-(tandem) mass spectrometry (LC-(MS/MS)
13approaches for quantification of AQS have been described by the group of Rahme for
14various purposes using selected-ion monitoring [20,21], full-scan monitoring [22], or
15selected reaction monitoring (SRM) [14]. However, for their purposes, they used
16Erlenmeyer flasks (large scale) for cultivation, rather long run times with conventional
17LC separation (26 - 69 min) [20-22], and complex extraction procedures [22], which is
18too material- and time-consuming for routine inhibitor testing. Furthermore, simple
19addition of methanolic internal standard (IS) solution [20,21] may lead to contamination
20of column and ion source and increase the risk of ion suppression or enhancement by
21co-eluting substances. This would be disadvantageous for routine inhibitor testing.

22 Ortori *et al.* [23] reported a validated LC-MS/MS method for quantitative profiling
23of AHLs and AQS. However, PQS was described to show extremely poor peak shapes,
24independently of the used stationary phase [22,23], resulting in unquantifiable peaks and
25irreproducible results. To overcome this drawback, the chelator EDTA was added to the

1 mobile phase with the risk of increased ion suppression and contamination of the MS
2 source.

3 During application of LC-MS/MS in routine testing [13,16], similar problems arose.
4 Therefore, the development and validation of a fast ultra-high performance liquid
5 chromatographic (UHPLC)-MS/MS procedure for reliable quantification of PQS in *P.*
6 *aeruginosa* culture in the presence of QSIs will be presented with the aim of developing
7 novel anti-infective drugs. Chemical derivatization, acetylation, was exploited to
8 overcome the described chromatographic irreproducibility.

9

10

11 2. Materials and methods

12

13 2.1. Chemicals and bacterial strains

14

15 Acetic anhydride, ammonium acetate (both of analytical grade), and yeast extract were
16 purchased from Fluka (Neu-Ulm, Germany), methanol, acetonitrile, ethyl acetate,
17 sodium chloride, and trifluoroacetic acid (TFA) (all of analytical grade) from VWR
18 (Darmstadt, Germany), pyridine (purissimum) and indole from Sigma Aldrich
19 (Schnelldorf, Germany), peptone from casein from Merck (Darmstadt, Germany), and 2-
20 amino-6-fluorobenzoic acid (6FABA) from Apollo Scientific (Stockport, UK). The
21 following substances were synthesized as reported: PQS [16], PQS-*d*₄ [21], and 2NPPM
22 [13]. The *P. aeruginosa* strain PA14 and its isogenic *pqsH* transposon mutant were
23 obtained from Prof. Susanne Häussler (Twincore, Hannover, Germany) and maintained
24 in glycerol stocks stored at - 80°C.

25

12.2. *Biosample for inhibitor assay*

2

3 *P. aeruginosa* PA14 cultures were inoculated with a starting $OD_{600} = 0.02$ in 24-well
4 Greiner Bio-One (Frickenhausen, Germany) Cellstar plates containing 1.5 mL of Luria-
5 Bertani broth (0.5%, w/v, NaCl; 0.5%, w/v, yeast extract; 1%, w/v, peptone from
6 casein) per well. Dimethylsulfoxide (DMSO) as a control or DMSO solutions of
7 inhibitors were added to the cultures to a final DMSO concentration of 1% (v/v). Plates
8 were incubated at 37°C, 200 rpm and a humidity of 75% for 16 h. For each inhibitor,
9 cultivations were performed in triplicate [13]. To 500 μ L of the cultures, 50 μ L of a
10 methanolic solution containing 100 μ M of the IS PQS-*d*₄ were spiked in 2-mL
11 Eppendorf tubes and processed as described below.

12

13.2.3. *Biosample for method development and validation (blank sample)*

14

15 *P. aeruginosa* PA14 isogenic *pqsH* mutant cultures were prepared as described for the
16 inhibition assay. After incubation, the cultures from all wells were pooled, mixed and
17 used freshly.

18

19.2.4. *Sample processing*

20

21 Ethyl acetate (1 mL) was added to the cultures samples, shaken on a rotary shaker for 5
22 min, and centrifuged for 5 min at 18,620 g. A 200- μ L aliquot of the ethyl acetate phase
23 was transferred to LC glass vials and evaporated to dryness at 35°C using a Thermo
24 Fisher Scientific (TF, Dreieich, Germany) Savant SpeedVac.

1 The evaporated samples were acetylated in the glass vials with 200 μ L of an acetic
2anhydride-pyridine mixture (3:2, v/v) for 10 min under microwave irradiation at 350 W
3according to the reported method [24]. After evaporation of the acetylation mixture at
460°C, the residues were dissolved in 400 μ L of methanol.

5

62.5. Apparatus

7

8The analyses were performed using a TF Accela UHPLC equipped with a degasser, a
9quaternary pump, and an autosampler (tray temperature 18°C) and coupled to a TF
10Accela photodiode-array detector (PDA) followed by a TF TSQ Quantum Access Max
11mass spectrometer with heated electrospray ionization source (HESI-II).

12 For gradient elution, a TF Accucore RP-MS column (150 x 2.1 mm, 2.6 μ m) was
13used with a mobile phase consisting of ammonium acetate buffer (0.01 M) containing
141% TFA (v/v; eluent A; final pH 2.75) and acetonitrile containing 1% TFA (v/v; eluent
15B) and a flow rate of 800 μ L/min under the following conditions: 0-6 min 5% to 100%
16A, 6-8 min hold, 8-8.1 min down to 5% A, 8.1-9 min hold for column equilibration with
17a total run time of 9 min. Column flushing was performed after 10 samples each with
18the same LC method. The injection volume was 5 μ L using partial loop injection mode.
19The divert valve was set to 3 min.

20 The PDA was operated in the wavelength full scan mode for monitoring the
21inhibitors and PQS after acetylation at concentrations of 1 mM each.

22 The following MS conditions were used: electrospray ionization (ESI), positive
23mode, sheath gas, nitrogen at a flow rate of 50 arbitrary units; auxiliary gas, nitrogen at
24flow rate of 15 arbitrary units; collision gas, argon; vaporizer temperature, 550°C; ion
25transfer capillary temperature, 150°C; capillary offset, 35 V; spray voltage, 1500 V.

1 The mass spectrometer was operated in the SRM mode. Transitions and their
2 particular settings, collision energy and tube lens, were determined using methanolic 10
3 μM solutions of PQS or PQS- d_4 injected after acetylation by the integrated syringe
4 pump and obtained using the TSQ Tune Master software in the optimization
5 MS+MS/MS mode.

6 According to the breakdown curves for diacetylated PQS (2acPQS; Fig. 1a), the
7 transition of the precursor ion at m/z 344 to ion at m/z 260 was selected at collision
8 energy of 27 V. Scan time was 0.1 s, scan width m/z 0.3, and tube lens offset 127 V. For
9 2acPQS- d_4 (Fig. 1b), the transition of the precursor ion at m/z 348 to ion at m/z 264 was
10 selected at collision energy of 27 V. Scan time was 0.1 s, scan width m/z 0.1, and tube
11 lens offset 133 V.

12 TF Xcalibur 2.2 software was used for data acquisition. The settings were as follows:
13 peak detection algorithm, genesis; smoothing, 7; signal to noise threshold, 0.5.
14 GraphPad Prism 5.00 (GraphPad Software, San Diego, CA, USA) was used for
15 statistical analysis.

16 The Fourier-transform infrared (FT-IR) spectrum of 2acPQS was recorded on a
17 PerkinElmer (Rodgau, Germany) Spectrum 100 FT-IR spectrometer.

18

19 2.6. Preparation of stock solutions, calibration standards, and quality control samples

20

21 Methanolic stock solutions of PQS or PQS- d_4 were prepared at a concentration of 1
22 mM. For preparation of the calibration standards, spiking solutions were mixed
23 containing 100 μM each of PQS- d_4 and 700, 525, 350, 175, 87.5, 21.88, 10.94, or 5.47
24 μM of PQS and for preparation of the quality control (QC) samples, spiking solutions
25 containing 100 μM each of PQS- d_4 and 600, 450, 300, 150, 9.38, or 5.47 μM PQS. All

1 spiking solutions were made by adding the appropriate amount of the corresponding
2 stock solution to obtain concentrations ten times higher than the final concentration in
3 culture. Calibration standards and QC samples were prepared by adding 50 μL of the
4 corresponding spiking solutions to 500 μL of blank samples and worked-up as described
5 above.

6

7 2.7.7. Selectivity and carry over

8

9 The following samples were tested for peaks interfering with the detection of 2acPQS
10 and/or 2acPQS- d_4 by monitoring the response in the 2acPQS- d_4 channel at regular
11 concentration and/or in the 2acPQS channel at the lower limit of quantification (LLOQ):
12 two processed blank samples each spiked with methanol, with PQS at the highest
13 calibrator concentration (final concentration 70 μM), or with PQS- d_4 (zero sample) at
14 regular concentration (final concentration 10 μM). In addition, with each batch of
15 validation samples, two processed blank samples spiked with methanol and two zero
16 samples each were analyzed in the same way.

17 Furthermore, carry over was investigated by analyzing a blank sample after injection
18 of the processed highest calibrator by monitoring the responses as described before.

19

20 2.8. Matrix effect, recovery and process efficiency

21

22 Matrix effect, recovery, and process efficiency were determined according to the
23 approach described by Matuszewski *et al.* [25]. Shortly, three sets of samples were
24 prepared at 8 different concentrations (Table 1). Each sample was prepared in
25 quadruplicate. Samples of set 1 represented the neat standard; samples of set 2 blank

1 samples spiked after extraction and samples of set 3 blank samples spiked before
2 extraction. All samples were acetylated. Absolute peak areas of samples of set 2 were
3 compared with those of set 1 to obtain matrix effect, of set 3 with those of set 2 to
4 determine recovery, and of set 3 with those of set 1 to achieve process efficiency. In case
5 of process efficiency and recovery, the values were corrected by the dilution factor.

6

7 2.9. Calibration model

8

9 Five replicates each of the calibration standards at each concentration level were
10 analyzed as described above. The regression lines (linear through zero or ignoring zero)
11 were calculated using a non-weighted, a weighted [1/concentration], and a weighted [1/
12 (concentration)²] least-squares regression model. Second-order models with the same
13 weighting factors were also calculated. The following statistical tests using GraphPad
14 software were performed: Grubbs' test for outliers, *F* test for heteroscedasticity, extra
15 sum-of-squares *F* test for model comparison.

16 For each batch of validation samples, calibration curves were prepared using the
17 same concentrations with single measurements per level. The back-calculated
18 concentrations of all calibration samples were compared with their respective nominal
19 values.

20

21 2.10. Full, one-point, and two-point calibration

22

23 Quantification was performed by comparing peak area ratios ($2acPQS/2acPQS-d_4$) to
24 calibration curves generated by plotting the peak areas of spiked calibrators against their
25 nominal concentrations. For full calibration, eight calibrators were used, for one-point

1 calibration, calibrators 1-8 each, and for two-point calibration, pairs of calibrators in all
2 possible combinations.

3

4 2.11. Accuracy and precision

5

6 The QC samples were analyzed in sextuplicate at each concentration level on each of
7 three days as recommended by the European Medicines Agency (EMA) guideline on
8 bioanalytical method validation
9 (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf) and processed as described above. The PQS concentrations in the
10 QC samples were calculated *via* the corresponding calibration curves. Accuracy was
11 expressed in terms of bias as the percental deviation of the mean calculated
12 concentration at each concentration level from the respective nominal concentration,
13 precision as the coefficient of variation (CV) as defined by EMA. Within-run accuracy
14 and precision were calculated based on data obtained within one single run on each of
15 the three days, between-run values based on mean data from the three days as defined by
16 EMA.

18

19 2.12. Processed sample stability

20

21 The processed sample stability under the conditions of UHPLC-MS/MS analysis was
22 estimated using QC samples at low (final concentration 0.938 μM) and high (final
23 concentration 60 μM) concentrations. After extraction and derivatization, the samples
24 were pooled at each concentration level and six aliquots each were injected under the
25 conditions of a regular analytical run at time intervals of 4 h over a total run time of 16

1h. The QC samples were analyzed against a freshly prepared calibration curve and the
2calculated concentrations were compared to the nominal concentrations to obtain bias
3values as recommended by EMA.

4

52.13. *Lower limit of quantification*

6

7The LLOQ was defined as the lowest point of the calibration curve, at which the
8response signal of 2acPQS was at least five times the signal of a blank sample and at
9which the acceptance criteria according to EMA for accuracy and precision were
10fulfilled.

11

122.14. *Proof of applicability*

13

14The effect of 2NPPM (250 μ M) [13] on the formation of PQS in *P. aeruginosa* PA14
15cultures was tested three times independently using the described inhibition assay with
16two-point calibration. In addition, the inhibitor concentration to achieve a half-maximal
17degree of inhibition (IC_{50}) was determined twice independently for 6FABA [14] or
18indole [26] using at least five different inhibitor concentrations tested at least in
19duplicate. Dose-response curves were obtained by plotting the percental inhibition of
20PQS formation versus the logarithm of inhibitor concentration. IC_{50} values were
21calculated with GraphPad Prism 5.00 software using nonlinear regression (four-
22parameter dose-response model).

23

243. **Results and discussion**

25

13.1. Biosamples

2

3For the biological evaluation of such inhibitors, a 24 well format-based bioassay using
4*P. aeruginosa* PA14 cultures was developed [13]. A PQS-deficient *P. aeruginosa* PA14
5isogenic *pqsH* mutant culture [8] was chosen as biosample for method development and
6validation. As in *pqsH* mutants only the last step of PQS biosynthesis is interrupted,
7whereas the formation of the biosynthetic precursors is conserved [11,20,27], this
8culture was considered as the most appropriate biosample.

9

103.2. Sample processing

11

12PQS was isolated from cultures by liquid-liquid extraction in order to reduce the risk of
13matrix effect and contamination of column and ion source. During method development,
14similar problems of unquantifiable peaks of PQS arose as described by Ortori *et al.* [23].
15As the hydroxy function was discussed to be responsible for the poor chromatographic
16behavior of PQS [19,23], chemical derivatization, in common use for GC-MS analysis
17[24], was investigated. Microwave-assisted acetylation proved to be superior to other
18derivatization methods such as trimethylsilylation, methylation by diazomethane or
19methyl iodide (according to ref. [24], data not shown). The described acetylation method
20was optimized concerning type of reaction vessels, volumes, energy, and reaction time.
21In the context of matrix effect, recovery, and process efficiency testing (see below), the
22peak areas for set 1 showed with CVs < 11% over the whole calibration range good
23reproducibility of the derivatization step. This derivatization procedure was fast,
24reproducible, and allowed complete removal of the derivatization reagents avoiding
25contamination of the LC-MS system in contrast to EDTA addition used by Ortori *et al.*

1[23]. The resulting 2acPQS and 2acPQS- d_4 greatly improved the chromatographic
2properties (Fig. 2) and provided reproducible quantification results (see section 3.4.).
3The diacetyl products are depicted in Fig. 1. The 3,4-substitution pattern was supported
4by FT-IR spectroscopy, as a double band between 1770 and 1760 cm^{-1} corresponding to
5reported carbonyl stretching vibrations of similar quinolone-derived di-esters [28] was
6observed in the spectrum but no band at around 1650 cm^{-1} excluding the *N*-acetylated
7product [29] This study illustrates that chemical derivatization is a powerful tool also in
8LC-MS analysis as already applied *e.g.* in pharmacokinetics [30] to improve detection
9specificity, ionization efficiency, sensitivity and chromatographic behavior of analytes.

10

113.3. Separation and detection by UHPLC-MS/MS

12

13A 6 min gradient was developed allowing fast sample analysis as well as separation of
14matrix components. Mass spectrometric detection was performed using positive ESI
15mode and monitoring the analytes in SRM mode. Ion at m/z 344 corresponded to the
16protonated parent mass of 2acPQS, whereas the respective mono- and non-acetylated
17fragments resulted in ions at m/z 302 and 260, respectively (Fig. 1a). Ions at m/z 188 and
18175 referred to fragments described for PQS by Lépine *et al.* [22]. For sensitivity
19reasons, transition m/z 344>260 was selected at collision energy of 27 V. The transition
20for the IS 2acPQS- d_4 was chosen accordingly (Fig. 1b). Only one transition was chosen
21in order to obtain enough data points for good reproducibility (even in two-point
22calibration).

23

243.4. Method validation

25

1 This method was validated according to the EMA guideline on bioanalytical method
2 validation wherever reasonable. In addition, the results for precision and accuracy
3 obtained with full and one-point or two-point calibration were systematically compared.

4

53.4.1. *Selectivity and carry over*

6

7 In order to assess selectivity of the method, processed blank samples spiked with
8 methanol, PQS, or PQS- d_4 were analyzed (Fig. 3). The areas of interfering peaks were
9 lower than 20% of the peak areas of 2acPQS at LLOQ or 5% of the peak area of PQS- d_4
10 thus fulfilling the criteria of selectivity according to EMA. Only two processed blank
11 samples each were tested because only one type of biomatrix was used, namely the
12 bacterial culture grown under standardized conditions.

13 However, compounds to be tested for PQS inhibition should be checked for
14 interference with 2acPQS and 2acPQS- d_4 . In case of co-elution, possible ion
15 suppression or enhancement should be excluded as described by Remane *et al.* [31].

16 Furthermore, carry over could be excluded as the response signals in the MS/MS
17 channels of 2acPQS and 2acPQS- d_4 in the blank sample following the high
18 concentration standard were within the acceptable ranges according to EMA. Therefore,
19 no additional wash steps were required between two injections.

20

213.4.2. *Matrix effect, recovery, and process efficiency*

22

23 As given in Table 1, matrix effects were in the range of 94-113% with CVs < 10%
24 indicating very low risk of interference even at low concentrations. In addition, the

1 values normalized by the IS PQS- d_4 were in the range of 99-102% with CVs < 2% and
2 thus considered as negligible.

3 As further given in Table 1, the recoveries for PQS and PQS- d_4 ranged from 94-
4 104% and 94-102%, respectively with CVs < 14%, and the process efficiencies from 92-
5 112% and 92-110%, respectively with CVs < 12%. Thus, these results demonstrated
6 good sample processing.

7

8 3.4.3. Calibration model

9

10 A calibration curve consisting of eight concentration levels with five replicates each was
11 constructed to evaluate the calibration model. Considering an amount of about 60 μM
12 PQS in incubated bacterial cultures (data not shown), a calibration range from 0.5-70
13 μM was chosen. Thus, reliable quantification of low PQS levels after strong inhibition
14 should be possible.

15 Because of unequal variances (heteroscedasticity) across the calibration range, a 1/
16 [concentration]² weighted calibration model was chosen. Comparing different regression
17 models, a second-order (quadratic) calibration turned out to be statistically the best.
18 Nevertheless, two linear regression models (one forced through zero, one ignoring zero)
19 were additionally used for assessing accuracy and precision in order to check whether
20 one-point [32] or two-point [33] calibration could be applicable saving time and
21 resources.

22

23 3.4.4. Accuracy and precision

24

1 For the calibration standards, the back-calculated concentrations fulfilled the acceptance
2 criteria of EMA (accuracy: bias $\leq 15\%$, $\leq 20\%$ at LLOQ; precision: CV $\leq 15\%$, $\leq 20\%$
3 at LLOQ). For determination of accuracy and precision, the QC samples were analyzed
4 in sextuplicate on each of 3 days. The obtained data applying full quadratic and the two
5 full linear calibrations are given in Table 2. According to the EMA guidelines, the
6 accuracy and precision data obtained after quadratic as well as after both full linear
7 calibrations fulfilled the acceptance criteria (accuracy: bias $\leq 15\%$, $\leq 20\%$ at LLOQ;
8 precision: CV $\leq 15\%$, $\leq 20\%$ at LLOQ).

9 For one-point calibration, accuracy and precision data for the QC samples were
10 calculated using calibrators 1-8 each as one-point calibrator. Calibrator 4 showed best
11 accuracy and precision data, which were therefore statistically compared to those
12 obtained by full calibration forced through zero as described by Remane *et al.* [34].
13 Briefly, the corresponding bias values (neglecting signs) were subjected to *t* tests and the
14 correspondent variance values submitted to *F* tests. Both tests indicated that full
15 calibration was significantly superior to one-point calibration. Thus, one-point
16 calibration was not considered to be acceptable [32].

17 In order to evaluate two-point calibration, accuracy and precision data for the QC
18 samples (Table 3) were calculated using calibrator pair 1/6, chosen according to Tan *et*
19 *al.* [33]. These data were systematically compared to the respective results calculated
20 with full linear calibration ignoring zero as described above, as this calibration was
21 superior to that through zero. Neither the *t* tests nor the *F* tests provided significant
22 differences ($p < 0.05$) at all concentration levels. Thus, two-point calibration ($y =$
23 $0.0001042x + 0.009397$) was accepted as the method of choice for routine testing saving
24 time and resources [33].

13.4.5. Stability of the processed sample

2

3In the processed QC samples, 2acPQS and 2acPQS-*d*₄ were stable for a period of at least
416 h at autosampler conditions of +18°C as the bias values were less than 6% thus
5fulfilling the EMA acceptance criteria. Long term and freeze/thaw stability tests were
6not performed because for routine inhibitor testing samples are always freshly prepared
7and do not need to be stored for a long time or subjected to freeze-thaw cycles.

8

93.4.6. Lower limit of quantification

10

11For the lowest calibrator, the analyte response was more than 5 times the response of a
12blank sample and accuracy and precision data fulfilled the EMA acceptance
13requirements (accuracy: bias $\leq 15\%$, $\leq 20\%$ at LLOQ; precision: CV $\leq 15\%$, $\leq 20\%$ at
14LLOQ). Thus, the method allowed the detection of low PQS levels after strong
15inhibition of its formation.

16

173.5. Application

18

19The new approach was tested for applicability by analyzing the effect of 2NPPM, a
20known QSI, on extracellular PQS levels in *P. aeruginosa* PA14 liquid cultures [13]. In
21Fig. 2, chromatograms are depicted of SRM transition *m/z* 344>260 indicating 2acPQS
22and transition *m/z* 348>264 indicating 2acPQS-*d*₄ in a processed *P. aeruginosa* PA14
23culture biosample after incubation without (a) or with 2NPPM (b). In accordance to ref.
24Storz [13], PQS formation was inhibited by 37±6% at an inhibitor concentration of 250
25µM. In addition, dose-dependent effects of the known QSIs 6FABA [14] and indole [26]

1 on PQS production were tested providing the following IC_{50} values: $109 (\pm 14) \mu\text{M}$ for
2 26FABA, and $236 (\pm 6) \mu\text{M}$ for indole (Fig. 4). 6FABA nearly abolished PQS production
3 at a concentration of 1.5 mM in accordance with the literature [14]. Tashiro *et al.* [26]
4 reported a concentration of indole for half-maximal inhibition of PQS synthesis of
5 around $50 \mu\text{M}$, which was lower than the IC_{50} value obtained in this study. However,
6 they used a different *P. aeruginosa* strain (PAO1) that produced less PQS than PA14
7 [21]. Separation of the acetylated inhibitors from 2acPQS and 2acPQS- d_4 was
8 demonstrated using the same LC system with PDA detection because the acetylated
9 inhibitors were not sufficiently ionized under the applied LC-MS conditions.

10

11

12 4. Conclusions

13

14 The described UHPLC-MS/MS method enables selective detection and accurate and
15 precise quantification of PQS in bacterial culture for monitoring the anti-QS activity of
16 test compounds. The procedure copes with the criteria of a validated method and was
17 shown to be efficient in routine application. The use of a two-point calibration in
18 combination with a simple and fast sample work-up allowed time- and cost-efficient
19 assay performance. Improvement of LC properties was a further example for the
20 advantageous use of chemical derivatization in LC-MS analysis. In summary, the
21 described approach is a useful tool in the discovery of new QSIs as potential anti-
22 infectives.

23

24 Acknowledgements

1The authors thank Prof. Susanne Häussler for providing the *P. aeruginosa* PA14 strain
2and the isogenic *pqsH* mutant, Dr. Johannes C. de Jong for synthesis of the standards as
3well as Dr. Stefan Boettcher, Julia Dinger, Dr. Matthias Groh, Dr. Markus R. Meyer,
4and Prof. Frank T. Peters for helpful discussions.

1References

2

3 [1] S.B. Levy, B. Marshall, Antibacterial resistance worldwide: causes, challenges
4 and responses, *Nat. Med.* 10 (2004) S122-S129.

5 [2] N. Hoiby, T. Bjarnsholt, M. Givskov, S. Molin, O. Ciofu, Antibiotic resistance
6 of bacterial biofilms, *Int. J. Antimicrob. Agents* 35 (2010) 322-332.

7 [3] L. Cegelski, G.R. Marshall, G.R. Eldridge, S.J. Hultgren, The biology and future
8 prospects of antivirulence therapies, *Nat. Rev. Microbiol.* 6 (2008) 17-27.

9 [4] V.C. Kalia, Quorum sensing inhibitors: an overview, *Biotechnol. Adv.* 31 (2013)
10 224-245.

11 [5] W.R. Galloway, J.T. Hodgkinson, S. Bowden, M. Welch, D.R. Spring,
12 Applications of small molecule activators and inhibitors of quorum sensing in
13 Gram-negative bacteria, *Trends Microbiol.* 20 (2012) 449-458.

14 [6] S. Swift, J.A. Downie, N.A. Whitehead, A.M. Barnard, G.P. Salmond, P.
15 Williams, Quorum sensing as a population-density-dependent determinant of
16 bacterial physiology, *Adv. Microb. Physiol* 45 (2001) 199-270.

17 [7] E.C. Pesci, J.B. Milbank, J.P. Pearson, S. McKnight, A.S. Kende, E.P.
18 Greenberg, B.H. Iglewski, Quinolone signaling in the cell-to-cell communication
19 system of *Pseudomonas aeruginosa*, *Proc. Natl. Acad. Sci. U. S. A* 96 (1999)
20 11229-11234.

21 [8] G. Xiao, E. Deziel, J. He, F. Lepine, B. Lesic, M.H. Castonguay, S. Milot, A.P.
22 Tampakaki, S.E. Stachel, L.G. Rahme, MvfR, a key *Pseudomonas aeruginosa*
23 pathogenicity LTTR-class regulatory protein, has dual ligands, *Mol. Microbiol.*
24 62 (2006) 1689-1699.

- 1 [9] K. Kim, Y.U. Kim, B.H. Koh, S.S. Hwang, S.H. Kim, F. Lepine, Y.H. Cho, G.R.
2 Lee, HHQ and PQS, two *Pseudomonas aeruginosa* quorum-sensing molecules,
3 down-regulate the innate immune responses through the nuclear factor-kappaB
4 pathway, *Immunology* 129 (2010) 578-588.
- 5 [10] M. Allesen-Holm, K.B. Barken, L. Yang, M. Klausen, J.S. Webb, S. Kjelleberg,
6 S. Molin, M. Givskov, T. Tolker-Nielsen, A characterization of DNA release in
7 *Pseudomonas aeruginosa* cultures and biofilms, *Mol. Microbiol.* 59 (2006) 1114-
8 1128.
- 9 [11] J.W. Schertzer, S.A. Brown, M. Whiteley, Oxygen levels rapidly modulate
10 *Pseudomonas aeruginosa* social behaviours via substrate limitation of PqsH,
11 *Mol. Microbiol.* 77 (2010) 1527-1538.
- 12 [12] D. Pistorius, A. Ullrich, S. Lucas, R.W. Hartmann, U. Kazmaier, R. Muller,
13 Biosynthesis of 2-Alkyl-4(1H)-quinolones in *Pseudomonas aeruginosa*: potential
14 for therapeutic interference with pathogenicity, *Chembiochem.* 12 (2011) 850-
15 853.
- 16 [13] M.P. Storz, C.K. Maurer, C. Zimmer, N. Wagner, C. Brengel, J.C. de Jong, S.
17 Lucas, M. Musken, S. Haussler, A. Steinbach, R.W. Hartmann, Validation of
18 PqsD as an anti-biofilm target in *Pseudomonas aeruginosa* by development of
19 small-molecule inhibitors, *J. Am. Chem. Soc.* 134 (2012) 16143-16146.
- 20 [14] B. Lesic, F. Lepine, E. Deziel, J. Zhang, Q. Zhang, K. Padfield, M.H.
21 Castonguay, S. Milot, S. Stachel, A.A. Tzika, R.G. Tompkins, L.G. Rahme,
22 Inhibitors of pathogen intercellular signals as selective anti-infective
23 compounds, *PLoS. Pathog.* 3 (2007) 1229-1239.
- 24 [15] T. Klein, C. Henn, J.C. de Jong, C. Zimmer, B. Kirsch, C.K. Maurer, D.
25 Pistorius, R. Muller, A. Steinbach, R.W. Hartmann, Identification of small-

- 1 molecule antagonists of the *Pseudomonas aeruginosa* transcriptional regulator
2 PqsR: biophysically guided hit discovery and optimization, *ACS Chem. Biol.* 7
3 (2012) 1496-1501.
- 4 [16] C. Lu, B. Kirsch, C. Zimmer, J.C. de Jong, C. Henn, C.K. Maurer, M. Musken,
5 S. Haussler, A. Steinbach, R.W. Hartmann, Discovery of antagonists of PqsR, a
6 key player in 2-alkyl-4-quinolone-dependent quorum sensing in *Pseudomonas*
7 *aeruginosa*, *Chem. Biol.* 19 (2012) 381-390.
- 8 [17] D.A. D'Argenio, M.W. Calfee, P.B. Rainey, E.C. Pesci, Autolysis and
9 autoaggregation in *Pseudomonas aeruginosa* colony morphology mutants, *J.*
10 *Bacteriol.* 184 (2002) 6481-6489.
- 11 [18] L. Zhou, F.J. Reen, F. O'Gara, C.M. McSweeney, S.L. Clarke, J.D. Glennon,
12 J.H. Luong, G.P. McGlacken, Analysis of *Pseudomonas* quinolone signal and
13 other bacterial signalling molecules using capillaries coated with highly charged
14 polyelectrolyte monolayers and boron doped diamond electrode, *J. Chromatogr.*
15 *A* 1251 (2012) 169-175.
- 16 [19] F. Bredenbruch, R. Geffers, M. Nimtz, J. Buer, S. Haussler, The *Pseudomonas*
17 *aeruginosa* quinolone signal (PQS) has an iron-chelating activity, *Environ.*
18 *Microbiol.* 8 (2006) 1318-1329.
- 19 [20] E. Deziel, F. Lepine, S. Milot, J. He, M.N. Mindrinos, R.G. Tompkins, L.G.
20 Rahme, Analysis of *Pseudomonas aeruginosa* 4-hydroxy-2-alkylquinolines
21 (HAQs) reveals a role for 4-hydroxy-2-heptylquinoline in cell-to-cell
22 communication, *Proc. Natl. Acad. Sci. U. S. A* 101 (2004) 1339-1344.
- 23 [21] F. Lepine, E. Deziel, S. Milot, L.G. Rahme, A stable isotope dilution assay for
24 the quantification of the *Pseudomonas* quinolone signal in *Pseudomonas*
25 *aeruginosa* cultures, *Biochim. Biophys. Acta* 1622 (2003) 36-41.

- 1 [22] F. Lepine, S. Milot, E. Deziel, J. He, L.G. Rahme, Electrospray/mass
2 spectrometric identification and analysis of 4-hydroxy-2-alkylquinolines (HAQs)
3 produced by *Pseudomonas aeruginosa*, *J. Am. Soc. Mass Spectrom.* 15 (2004)
4 862-869.
- 5 [23] C.A. Ortori, J.F. Dubern, S.R. Chhabra, M. Camara, K. Hardie, P. Williams,
6 D.A. Barrett, Simultaneous quantitative profiling of N-acyl-L-homoserine
7 lactone and 2-alkyl-4(1H)-quinolone families of quorum-sensing signaling
8 molecules using LC-MS/MS, *Anal. Bioanal. Chem.* 399 (2011) 839-850.
- 9 [24] H.H. Maurer, K. Pflieger, A.A. Weber, *Mass Spectral and GC Data of Drugs,*
10 *Poisons, Pesticides, Pollutants and their Metabolites*, fourth ed., Wiley-VCH,
11 Weinheim, 2011.
- 12 [25] B.K. Matuszewski, M.L. Constanzer, C.M. Chavez-Eng, Strategies for the
13 assessment of matrix effect in quantitative bioanalytical methods based on
14 HPLC-MS/MS, *Anal. Chem.* 75 (2003) 3019-3030.
- 15 [26] Y. Tashiro, M. Toyofuku, T. Nakajima-Kambe, H. Uchiyama, N. Nomura,
16 Bicyclic compounds repress membrane vesicle production and *Pseudomonas*
17 quinolone signal synthesis in *Pseudomonas aeruginosa*, *FEMS Microbiol. Lett.*
18 304 (2010) 123-130.
- 19 [27] F. Bredenbruch, M. Nimtz, V. Wray, M. Morr, R. Muller, S. Haussler,
20 Biosynthetic pathway of *Pseudomonas aeruginosa* 4-hydroxy-2-alkylquinolines,
21 *J. Bacteriol.* 187 (2005) 3630-3635.
- 22 [28] T.W.M. Spence, G. Tennant, *The chemistry of nitro-compounds. Part 1. Acid-*
23 *catalysed ring-opening reactions of substituted o-nitrophenylethylene oxides*
24 *involving participation by the nitro-group*, *J. Chem. Soc. (C)* (1971) 3712-3719.

- 1 [29] M.R. Del Giudice, G. Settimj, Proton and carbon nuclear magnetic resonance
2 study on some n- and o-acyl derivatives of monohydroxypyridines, *Tetrahedron*
3 40 (1984) 4067-4080.
- 4 [30] M. Niwa, Chemical derivatization as a tool for optimizing MS response in
5 sensitive LC-MS/MS bioanalysis and its role in pharmacokinetic studies,
6 *Bioanalysis*. 4 (2012) 213-220.
- 7 [31] D. Remane, M.R. Meyer, D.K. Wissenbach, H.H. Maurer, Ion suppression and
8 enhancement effects of co-eluting analytes in multi-analyte approaches:
9 systematic investigation using ultra-high-performance liquid
10 chromatography/mass spectrometry with atmospheric-pressure chemical
11 ionization or electrospray ionization, *Rapid Commun. Mass Spectrom.* 24 (2010)
12 3103-3108.
- 13 [32] F.T. Peters, H.H. Maurer, Systematic comparison of bias and precision data
14 obtained with multiple-point and one-point calibration in six validated
15 multianalyte assays for quantification of drugs in human plasma, *Anal. Chem.* 79
16 (2007) 4967-4976.
- 17 [33] A. Tan, K. Awaiye, B. Jose, P. Joshi, F. Trabelsi, Comparison of different linear
18 calibration approaches for LC-MS bioanalysis, *J. Chromatogr. B Analyt.*
19 *Technol. Biomed. Life Sci.* 911 (2012) 192-202.
- 20 [34] D. Remane, M.R. Meyer, D.K. Wissenbach, H.H. Maurer, Full validation and
21 application of an ultra high performance liquid chromatographic-tandem mass
22 spectrometric procedure for target screening and quantification of 34
23 antidepressants in human blood plasma as part of a comprehensive multi-analyte
24 approach, *Anal. Bioanal. Chem.* 400 (2011) 2093-2107.

1 Figure captions

2

3 **Fig. 1.** Structures and breakdown curves of the precursor ion at m/z 344 for 2acPQS (a)
4 and of that at m/z 348 for 2acPQS- d_4 (b).

5

6 **Fig. 2.** Chromatograms of SRM transition m/z 344>260 indicating 2acPQS and
7 transition m/z 348>264 indicating 2acPQS- d_4 in a processed *P. aeruginosa* PA14 culture
8 biosample after incubation without (a) or with 2NPPM (b).

9

10 **Fig. 3.** Chromatograms of SRM transition m/z 344>260 (2acPQS) and transition m/z
11 348>264 (2acPQS- d_4) of processed blank samples spiked with methanol (a), with 70
12 μ M PQS (b), or with 10 μ M PQS- d_4 (zero sample).

13

14 **Fig. 4.** Dose-response plots for the QSIs 6FABA (a) and indole (b). Mean values of $n \geq$
15 2, error bars represent standard deviation.

16

17

1 **Table 1** Calibrator number, nominal concentration, matrix effect, recovery, and process efficiency data (mean of n = 4, CV %)

2

| Calibrator number | Nominal concentration | Matrix effect % | | | Recovery % | | Process efficiency % | |
|----------------------|--------------------------|-----------------|------------|----------------|------------|------------|----------------------|------------|
| | | (CV %) | | | (CV %) | | (CV %) | |
| | [nM] | PQS | PQS- d_t | PQS/PQS- d_t | PQS | PQS- d_t | PQS | PQS- d_t |
| 1 | 547 | 113 (8) | 111 (8) | 102 (0) | 100 (4) | 96 (4) | 112 (10) | 106 (10) |
| 2 | 1094 | 112 (10) | 112 (10) | 101 (2) | 94 (2) | 92 (2) | 110 (12) | 106 (12) |
| 3 | 2188 | 109 (1) | 109 (2) | 100 (1) | 96 (3) | 94 (3) | 104 (4) | 102 (5) |
| 4 | 8750 | 105 (8) | 106 (8) | 99 (1) | 98 (7) | 96 (7) | 102 (3) | 100 (3) |
| 5 | 17500 | 103 (3) | 104 (3) | 99 (1) | 98 (4) | 98 (4) | 102 (4) | 102 (4) |
| 6 | 35000 | 97 (7) | 98 (8) | 99 (1) | 96 (13) | 94 (14) | 92 (8) | 92 (7) |
| 7 | 52500 | 107 (6) | 108 (6) | 99 (1) | 104 (2) | 102 (2) | 110 (8) | 110 (7) |
| 8 | 70000 | 94 (3) | 95 (3) | 99 (1) | 102 (4) | 100 (5) | 96 (7) | 94 (8) |

3

1 **Table 2** Nominal concentration, within- and between-run accuracy, within- and between-run precision for QC samples 1-6 (n = 6) calculated using full 1/x²
 2 weighted quadratic, linear (forced through zero), or linear (ignoring zero) calibration

3

| Calibration model | | Full calibration, quadratic, 1/x ² | | | | | | Full calibration, linear, force, 1/x ² | | | | | | Full calibration, linear, ignore, 1/x ² | | | | | | |
|--------------------|-------------|-----------------------------------------------|-------|------|------|------|------|---------------------------------------------------|-------|------|------|------|------|----------------------------------------------------|-------|------|------|------|------|------|
| QC sample | | QC 1 | QC 2 | QC 3 | QC 4 | QC 5 | QC 6 | QC 1 | QC 2 | QC 3 | QC 4 | QC 5 | QC 6 | QC 1 | QC 2 | QC 3 | QC 4 | QC 5 | QC 6 | |
| Nominal conc. [μM] | | 0.547 | 0.938 | 15 | 30 | 45 | 60 | 0.547 | 0.938 | 15 | 30 | 45 | 60 | 0.547 | 0.938 | 15 | 30 | 45 | 60 | |
| Accuracy | Within-run | Day 1 | -11.8 | -8.9 | -1.5 | -1.0 | -0.2 | 0.4 | 6.6 | 0.3 | -5.3 | -6.0 | -6.2 | -6.5 | -12.7 | -8.7 | -0.5 | -0.8 | -0.9 | -1.1 |
| | | Day 2 | -6.6 | -3.5 | 3.4 | 3.9 | 4.4 | 4.9 | 11.1 | 5.1 | -0.7 | -1.3 | -1.6 | -1.9 | -7.2 | -3.3 | 4.2 | 4.0 | 3.8 | 3.6 |
| | | Day 3 | 3.3 | 1.5 | 2.2 | 2.6 | 3.4 | 3.9 | 15.7 | 7.7 | -0.5 | -1.1 | -1.2 | -1.5 | 2.8 | 1.8 | 3.0 | 2.7 | 2.7 | 2.5 |
| Bias [%] | Between-run | | -5.0 | -3.6 | 1.4 | 1.8 | 2.5 | 3.1 | 11.1 | 4.3 | -2.2 | -2.8 | -3.0 | -3.3 | -5.7 | -3.4 | 2.2 | 2.0 | 1.9 | 1.7 |
| | | | | | | | | | | | | | | | | | | | | |
| Precision | Within-run | Day 1 | 0.9 | 0.6 | 0.6 | 0.7 | 0.7 | 0.6 | 0.7 | 0.5 | 0.6 | 0.7 | 0.7 | 0.6 | 1.0 | 0.6 | 0.6 | 0.7 | 0.7 | 0.6 |
| | | Day 2 | 1.5 | 1.0 | 0.7 | 0.5 | 0.7 | 0.5 | 1.2 | 0.9 | 0.7 | 0.5 | 0.7 | 0.5 | 1.5 | 1.0 | 0.7 | 0.5 | 0.7 | 0.5 |
| | | Day 3 | 1.6 | 1.4 | 1.0 | 1.0 | 1.0 | 1.3 | 1.4 | 1.3 | 1.0 | 1.0 | 0.9 | 1.3 | 1.7 | 1.4 | 1.0 | 1.0 | 0.9 | 1.3 |
| CV [%] | Between-run | | 8.0 | 5.4 | 2.5 | 2.5 | 2.4 | 2.3 | 4.1 | 3.6 | 2.8 | 2.9 | 2.9 | 2.9 | 8.3 | 5.5 | 2.4 | 2.4 | 2.4 | 2.4 |
| | | | | | | | | | | | | | | | | | | | | |
| | run | | | | | | | | | | | | | | | | | | | |

4

2 **Table 3** Nominal concentration, within- and between-run accuracy, within- and between-run precision for QC samples 1-6 (n = 6) calculated using one-point
3 or two-point calibration

4

| Calibration model | | One-point calibration (calibrator 4) | | | | | | Two-point calibration (calibrator pair 1/6) | | | | | | |
|---------------------------------|-------------|--------------------------------------|-------|------|------|------|------|---------------------------------------------|-------|------|------|------|------|------|
| QC sample | | QC 1 | QC 2 | QC 3 | QC 4 | QC 5 | QC 6 | QC 1 | QC 2 | QC 3 | QC 4 | QC 5 | QC 6 | |
| Nominal conc. [μM] | | 0.547 | 0.938 | 15 | 30 | 45 | 60 | 0.547 | 0.938 | 15 | 30 | 45 | 60 | |
| Accuracy | Within- | Day 1 | 9.5 | 3.0 | -2.7 | -3.4 | -3.7 | -4.0 | -12.3 | -8.3 | -0.1 | -0.4 | -0.5 | -0.7 |
| | | Day 2 | 14.4 | 8.1 | 2.2 | 1.5 | 1.1 | 1.0 | -7.0 | -3.2 | 4.2 | 4.0 | 3.6 | 3.6 |
| | | Day 3 | 17.6 | 9.5 | 1.2 | 0.6 | 0.2 | 0.2 | 2.7 | 1.9 | -3.1 | -2.8 | -2.6 | -2.6 |
| Bias [%] | Between-run | 13.8 | 6.9 | 0.2 | -0.4 | -0.5 | -0.9 | -5.5 | -3.2 | -2.4 | -2.1 | -2.1 | -1.8 | |
| | Within-run | Day 1 | 0.7 | 0.5 | 0.6 | 0.7 | 0.7 | 0.6 | 1.0 | 1.0 | 0.6 | 0.7 | 0.7 | 0.6 |
| Precision | Within-run | Day 2 | 1.2 | 0.9 | 0.7 | 0.5 | 0.7 | 0.5 | 1.5 | 1.0 | 0.7 | 0.5 | 0.7 | 0.5 |
| | | Day 3 | 1.4 | 1.3 | 1.0 | 1.0 | 0.6 | 1.3 | 1.7 | 1.4 | 1.0 | 1.0 | 0.6 | 1.3 |
| | | Between-run | 3.6 | 3.2 | 2.6 | 2.6 | 2.7 | 2.7 | 8.1 | 5.3 | 2.1 | 2.2 | 2.2 | 2.2 |
| CV [%] | Between-run | 3.6 | 3.2 | 2.6 | 2.6 | 2.7 | 2.7 | 8.1 | 5.3 | 2.1 | 2.2 | 2.2 | 2.2 | |
| | run | | | | | | | | | | | | | |

5